Develops nanocrystal drug candidates for people with central nervous system disorders and sells mineral dietary supplements through a subsidiary and licensee.
10-K for FY2025, filed Mar 17, 2026Our development and clinical efforts are dedicated to revolutionizing the treatment of neurodegenerative diseases to restore and protect…View ↗
Our lead drug asset, CNM-Au8, is a highly concentrated aqueous suspension of catalytically-active, clean-surfaced, faceted gold…View ↗
Dietary supplements are marketed and distributed through our wholly-owned subsidiary, dOrbital, Inc. (“dOrbital”), or through an exclusive…View ↗
Clene earns money from dietary supplement sales and royalties on supplement sales. Commercial customers pay upon receipt, while online retail customers prepay; the company fulfills supplement orders by delivery.
10-K for FY2025, filed Mar 17, 2026Once a contract is determined to be within the scope of ASC 606 at contract inception, we review the contract to determine which…View ↗
10-K for FY2025, filed Mar 17, 2026
FY2025 revenue by product or service ↗$200K
10-K for FY2025, filed Mar 17, 2026
$200K ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product
Sold outright
10-K for FY2025, filed Mar 17, 2026 |
60%
FY2022: 70%
|
Product, FY2025
$119K Sources
|
Sold outright |
|
Royalty
Licensed
10-K for FY2025, filed Mar 17, 2026 |
41%
FY2022: 30%
|
Royalty, FY2025
$81K Sources
|
Licensed |
Supplement customers buy through dOrbital or 4Life: dOrbital sells rMetx, while 4Life sells Zinc Factor under a supply agreement and markets Gold Factor under an exclusive worldwide license.
10-K for FY2025, filed Mar 17, 2026Dietary supplements are marketed and distributed through our wholly-owned subsidiary, dOrbital, Inc. (“dOrbital”), or through an exclusive…View ↗
rMetx™ (ZnAg Immune Boost) by dOrbital is an aqueous zinc-silver ion dietary (mineral) supplement made using our electrochemistry…View ↗
KHC46 (Gold Factor™) by 4Life is an aqueous gold dietary (mineral) supplement of very low-concentration gold nanoparticles produced using…View ↗
No. It lost $26.2M in FY2025.
10-Q for Q3 FY2026, filed Nov 4, 2026
$3.9MView ↗
10-Q for Q3 FY2026, filed Nov 4, 2026
Open tableView ↗
Shrinking. Revenue fell 72% in 4 years, from $723K in FY2021 to $200K in FY2025, about 27% a year.
Loading...